Aldeyra Therapeutics, Inc. (NASDAQ: ALDX), a clinical stage company based in Lexington, Massachusetts, has reported the initiation of a Phase 2 clinical trial of ADX-2191… Read More »Aldeyra Therapeutics Inc., (NASDAQ: ALDX) reports the launch of a Phase 2 study for methotrexate to treat Pro23His retinitis pigmentosa (RP)
A research study, conducted in the Department of Mechanical Engineering and School of Optometry and Vision Science at the University of Auckland, New Zealand, has… Read More »A systematic review on electronic vision prostheses suggest several improvements on methodology in order to show benefit
Foundation Fighting Blindness (FFB) are to invite a “Patient-Focused Drug Development” meeting, in the coming months, with Food and Drug Administration (FDA) representatives. The objective… Read More »X-linked Retinitis pigmentosa (XLRP) participants are invited to “My Retina Tracker Registry”, supported by Foundation Fighting Blindness
by Dr. Gearóid Tuohy Dear EURETINA Members, A very warm welcome to the March 17th, 2022 edition of EURETINA’s web-based digital magazine,… Read More »March 17th, 2022 “EURETINA-Brief”© Issue No. 251
A Dutch biotechnology company, ProQR Therapeutcis N.V., (NASDAQ:PRQR), Leiden, has announced the results of a Phase 2/3 study for the treatment of Leber Congenital Amaurosis… Read More »ProQR Therapeutics N.V. (NASDAQ: PRQR), announces top-line results for the treatment of a novel RNA therapy (“Sepofarsen [QR-110]”) for LCA10
A research study conducted in the Medical Genetics Program of Southwestern Ontario, London Health Sciences Centre, London, Canada has shown that there are a range… Read More »Perspectives from young adults with Leber congenital amaurosis (LCA) show complex factors when considering gene therapy and trial participation
Researchers at the Instituto de Investigación Sanitaria–Fundación Jiménez Díaz University Hospital, Universidad Autónoma de Madrid, has reported valuable clinical re-classifications from inherited dystrophies following next-generation… Read More »Next-generation sequencing data on inherited macular dystrophies (MD) shows significant impact among 1,036 Spanish families
by Dr. Gearóid Tuohy Dear EURETINA Members, A very warm welcome to the February 28th, 2022 edition of EURETINA’s web-based digital magazine,… Read More »February 28th, 2022 “EURETINA-Brief”© Issue No. 250
A French bioelectronics company “Pixium Vision SA”, based in Paris, has announced the implantation of an artificial retina in a first patient in the UK. … Read More »Pixium SA has announced the first UK patient enrolled in a “PRIMAvera” study with the implantation of a bionic artificial retina
A research study assessing patient and retina specialists’ preferences on the treatment of nAMD has shown a valuable comparison on specific measures. The “relative importance”… Read More »Preferences on neovascular age-related degeneration (nAMD) treatment shows clinicians and patients’ views on options